Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

BJU International

Volumn 106, Issue 10, 2010, Pages 1473-1476

  Taxel, Pamela ^a   Dowsett, Robert ^a   Richter, Lee ^a   Fall, Pamela ^a   Klepinger, Alison ^a   Albertsen, Peter ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

androgen deprivation; osteoporosis; prostate cancer

Indexed keywords

25 HYDROXYVITAMIN D; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; GONADORELIN AGONIST; PARATHYROID HORMONE; PLACEBO; PROCOLLAGEN; RISEDRONIC ACID; VITAMIN D;

ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE TURNOVER; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMUR NECK; HIP; HUMAN; LUMBAR SPINE; MALE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; EPIDEMIOLOGIC METHODS; ETIDRONIC ACID; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 78349255563     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09329.x     Document Type: Article

References (16)

1. Smith MR,. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247-54
2. Barry MJ, Delorenzo MA, Walker-Corkery ES, et al. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 2006; 98: 973-8
3. Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6
4. Israeli RS, Ryan CW, Jung LL,. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 2008; 179: 414-23
5. Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-903
6. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-64
7. Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175: 136-9
8. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001; 92: 1444-50
9. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001; 345: 948-55
10. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-42
11. Greenspan SL, Nelson JB, Trump DL, et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. Ann Intern Med 2007; 146: 416-24
12. Morote J, Orsola A, Abascal J, et al. Bone mineral density changes in prostate cancer patients in the first two years of androgen suppression. J Urol 2006; 175: 1679-83
13. Ishizaka K, Machida T, Kobayashi S, et al. Preventative effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer. Int J Urol 2007; 14: 1071-5
14. Planas J, Trilla E, Raventos C, et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 2009; 104: 1637-40
15. Izumi K, Mizokami A, Sugimoto K, et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009; 73: 1342-6
16. Moro-Alvarez MJ, Díaz-Curiel M,. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clin Interv Aging 2008; 3: 227-32